´ëÇѾÏÇÐȸ Á¦2ȸ Korean Immuno-Oncology Symposium : 2019-03-08±³À°ÀÏÀÚ : 2019-03-08
±³À°Àå¼Ò : ¼¿ï·Ôµ¥È£ÅÚ 2Ãþ Å©¸®½ºÅ»º¼·ë
±³À°ÁÖÁ¦ :
Á¦2ȸ Korean Immuno-Oncology SymposiumÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : »ç¹«±¹
¿¬¶ôó : 02-792-1486
À̸ÞÀÏ :
cancer4@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢±â°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаúÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 700¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í 1. »çÀüµî·Ï: 1) ¾ÏÇÐȸ/¸é¿ªÇÐȸ ȸ¿ø: 4¸¸¿ø, 2)ºñȸ¿ø: 5¸¸¿ø, 3) Trainee: 3¸¸¿ø 2. ÇöÀåµî·Ï: 1) ¾ÏÇÐȸ/¸é¿ªÇÐȸ ȸ¿ø: 6¸¸¿ø, 2) ºñȸ¿ø: 7¸¸¿ø, 3) Trainee: 4¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 09:10~09:40 Impact of tumor-associated macrophages in tumor hypoxia and aerobic glycolysis ¾ÈÁö¿Ï(Æ÷Ç×°ø´ë)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 09:40~10:10 Reconstructing the tumor microenvironment using high dimensional single-cell analysis Michael Wong(MSD)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 10:10~10:40 Understanding TME biology using genomic analysis of tumor cell Steven M. Townson(MSD/Merck research Lab)
ÈÞ½Ä 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 10:40~11:00 Coffee Break ()
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 11:00~11:30 Intrinsic tumor vaccination ±èÀλê(Çѱ¹°úÇбâ¼ú¿¬±¸¿ø)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 11:30~12:00 Myeloid-derived suppressor cells: A new therapeutic target to overcome resistance to checkpoint blockade therapy ¿¬Á¦ÀÎ(ÇÁ·ÎÁ¨)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 12:00~12:30 Oncolytic virus in cancer immunotherapy ¶ó¼±¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 12:30~13:30 How immunotherapy is revolutionising 1L and 2L lung cancer care Á¤Çö¾Ö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 13:30~13:30 Bringing Clarity to Clinical Decisions in RCC and GC: Translating Data Into Practice ¹è¿ì±Õ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 13:40~14:10 Current status of immunotherapy for glioblastoma Michael Lim(Johns Hopkins University School of Medicine)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 14:10~14:40 Evidences of IO combination with standard of care: Lessons from breast cancer ¹ÚÀÎÇý(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 14:40~15:10 Genomics, is immunotherapy right for me? ÀÌ´ëÈ£(¿ï»êÀÇ´ë)
ÈÞ½Ä 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 15:10~15:30 Coffee Break ()
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 15:30~15:50 Enhancing cancer immunotherapy using biomaterials ¹Úõ±Ç(¼º±Õ°ü´ë)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 15:50~16:10 NK cell-based cancer immunotherapy for refractory cancer ÃÖÀÎÇ¥(Çѱ¹»ý¸í°øÇבּ¸¿ø)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 16:10~16:30 Development of small molecule based immunotherapeutics for innovative anti-cancer treatment ÀÌâÈÆ(Çѱ¹ÈÇבּ¸¿ø)
±³À°½Ã°£ 03-08 ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë 16:30~16:50 PharmAbcine and its immuno oncology strategy- Tanibirumab + IO combo- IO Bispecific - Beyond PD1/PDL1 À¯Áø»ê(Æĸã½Å)